The Fc gamma receptor IIa (FcγRIIa, encoded by FCGR2A) is the immune system's main sensor for IgG-coated threats. Displayed on the surface of macrophages, neutrophils, and dendritic cells, it binds the tail region (Fc) of IgG antibodies and triggers phagocytosis — the engulfing and destruction of bacteria, viral immune complexes, and cellular debris. rs511278 is an intronic variant in FCGR2A that sits within the same haplotype block¹¹ haplotype block
A segment of DNA inherited together because variants within it are in strong linkage disequilibrium — they rarely separate during recombination as the classical functional variant rs1801274 (H131R). The T allele at rs511278 co-segregates with the histidine-131 (H131) form of FcγRIIa — the receptor variant that binds IgG2 efficiently. The C allele at rs511278 co-segregates with the arginine-131 (R131) form, which barely binds IgG2 at all.

The Mechanism

The H131R substitution at position 131 of the mature FcγRIIa protein changes a histidine to an arginine in the second immunoglobulin-like domain²² immunoglobulin-like domain
A structural fold shaped like an antibody constant region domain; FcγRIIa has two of these Ig-like domains that directly contact the Fc region of IgG of the receptor. This single amino acid swap has a major functional consequence: H131 binds IgG2 and IgG3 efficiently, while R131 barely interacts with IgG2 at all — and IgG2 is the dominant antibody subclass produced against polysaccharide antigens on the surface of encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae.

The two alleles are co-dominantly expressed, meaning heterozygotes (CT at rs511278, corresponding to H131/R131) have intermediate receptor function between the two homozygous states. The T allele at rs511278 is the minor allele globally (~18%), but its frequency varies substantially by ancestry: ~21% in Europeans, ~12% in Africans, and only ~7% in East Asians.

Because rs511278 is intronic and not itself the functional change, the biological effects described here derive from its linkage disequilibrium³³ linkage disequilibrium
The statistical tendency for two nearby alleles to be inherited together; when LD is high, an intronic tag SNP reliably predicts which functional allele is present with rs1801274 (H131R). The T allele tags H131; the C allele tags R131.

The Evidence

The highest-confidence association is Kawasaki disease (KD), a vasculitis predominantly affecting children under 5 that causes coronary artery aneurysms. The 2011 landmark GWAS by Khor et al.⁴⁴ landmark GWAS by Khor et al.
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nature Genetics, 2011 — 2,173 KD cases and 9,383 controls across five international cohorts — identified rs1801274 as the lead SNP at this locus (P = 7.35×10⁻¹¹, OR = 1.32 per A allele). The A allele at rs1801274 corresponds to H131 — the same haplotype tagged by the T allele at rs511278. Higher IgG-mediated immune activation from H131 may contribute to the disproportionate vasculitis response in KD-susceptible children.

A meta-analysis of 6 KD studies⁵⁵ meta-analysis of 6 KD studies
Association between FCGR2A rs1801274 H131R polymorphism and risk of Kawasaki disease. PLoS ONE, 2015 with 1,709 cases and 3,207 controls found H/H homozygotes had OR = 1.97 (95% CI 1.55–2.50) versus R/R homozygotes. The association was significant in Asians but not Caucasians — consistent with the lower H131 (T allele) frequency in East Asians, where the variant is rarer and cases carrying it have a proportionally larger genetic signal.

The SLE picture is the mirror image⁶⁶ SLE picture is the mirror image
Comprehensive Assessment of FCGRs polymorphisms and SLE risk. Arthritis Research and Therapy, 2016: the A allele (H131, tagged by T at rs511278) is protective against overall SLE susceptibility (OR = 0.879 per A allele, P = 3.31×10⁻⁴), but the R131 allele (C at rs511278) is specifically associated with lupus nephritis severity in some populations. This apparent paradox reflects that H131's efficient IgG immune complex clearance protects against SLE development (preventing accumulation of inflammatory complexes) while paradoxically contributing to immune hyperactivation in conditions like KD.

For infectious disease, the consequence reverses again⁷⁷ consequence reverses again
Protective Effects of FCGR2A Polymorphism in Invasive Pneumococcal Diseases. Chest, 2012: R/R homozygotes (CC at rs511278) showed 75% lower hospital mortality in severe invasive pneumococcal disease (OR 0.251, P = .004). The proposed mechanism is that the H131 allele, while enabling better phagocytic clearance, may also drive a more intense and potentially damaging inflammatory response in severe systemic infections. Meanwhile, for pneumococcal vaccination⁸⁸ pneumococcal vaccination
Pneumococcal vaccine efficacy for mucosal infections depends on FcγRIIa polymorphism. Vaccine, 2005, the H131 allele is critical: R/R homozygotes show significantly higher recurrence of acute otitis media after pneumococcal vaccination, as IgG2 antibodies induced by the vaccine cannot efficiently engage R131 receptors on phagocytic cells.

In COVID-19, a 2022 ICU cohort study⁹⁹ 2022 ICU cohort study
FCGR2A rs1801274 polymorphism associated with risk of death among COVID-19 patients. Scientific Reports, 2022 found the G allele (R131) was associated with increased mortality (OR = 1.47), with the dominant model (GG + AG vs AA) yielding OR = 2.22. This aligns with the IgG2-clearing hypothesis: H131 carriers clear viral immune complexes more efficiently.

Practical Actions

The clinical picture is inherently bidirectional: the T allele (H131 haplotype) confers both immune advantages (better vaccination response, better viral and bacterial immune complex clearance) and immune risks (higher KD susceptibility, possible contribution to inflammatory overactivation). For TT homozygotes, awareness of KD family history and monitoring for autoimmune triggers is appropriate. For CC homozygotes (R131 haplotype), vaccine responses to IgG2-dependent immunizations (pneumococcal polysaccharide vaccines) may be attenuated, and infection surveillance is warranted.

Interactions

rs511278 is in the same haplotype block as rs1801274 (H131R missense), meaning these two SNPs typically co-occur and should be interpreted together. The functional variant rs396991 in FCGR3A (V158F, CD16a) operates through a complementary but distinct receptor pathway — FcγRIIIa is expressed on NK cells and mediates ADCC, while FcγRIIa on phagocytes mediates opsonophagocytosis. Combined low-affinity genotypes at both FCGR2A and FCGR3A may compound impaired IgG-mediated immune responses.

The X chromosome contains far fewer genes than autosomes, and its contribution to testosterone biology in men was largely overlooked until large genome-wide association studies began scanning the full genome including sex chromosomes. rs5934505 sits in the Xp22 region in a structural variant-rich zone between two genes, FAM9B and FAM9A¹¹ FAM9B and FAM9A
family with sequence similarity 9, members B and A — both encoded on the X chromosome and expressed exclusively in the testis, approximately 79 kb downstream of FAM9B and 145 kb upstream of FAM9A. Despite being in a gene-sparse intergenic region, this SNP has reached genome-wide significance for serum testosterone concentrations in men across multiple independent GWAS cohorts. It represents one of only a handful of replicated genetic loci influencing circulating testosterone levels.

The Mechanism

The precise molecular mechanism by which rs5934505 influences testosterone has not been established. Both FAM9B and FAM9A are expressed almost exclusively in the testis — specifically in spermatogenic cells — making them prime candidates for regulatory elements that govern Leydig cell androgen synthesis or spermatogenic feedback on testosterone production. As an intergenic variant in a known copy-number variable (CNV) region on Xp22, rs5934505 may tag a regulatory element affecting the transcription of one or both flanking genes, with downstream effects on steroidogenesis in testicular tissue. Because the locus is on the X chromosome, the effect is hemizygous in men — each male carries exactly one copy (T or C), with no heterozygous intermediate. Women carry two copies and can be TT, TC, or CC.

The T allele is the reference/major allele, present in approximately 73% of chromosomes globally. Despite being common, the T allele is associated with lower serum testosterone. This is an example of the common-variant, common-phenotype pattern where the major allele at a locus defines a disadvantageous baseline — the C allele (minor allele, ~27%) appears to be the ancestrally-derived testosterone-promoting variant retained at moderate population frequency by either selection or drift.

The Evidence

The primary discovery study, Ohlsson et al. 2011 (PLoS Genetics), conducted a GWAS meta-analysis across 10 independent cohorts totaling 14,429 Caucasian men²² Ohlsson et al. 2011 (PLoS Genetics), conducted a GWAS meta-analysis across 10 independent cohorts totaling 14,429 Caucasian men
Genetic determinants of serum testosterone concentrations in men, finding rs5934505 at a combined p=5.6×10⁻¹⁶ for total testosterone and calculated free testosterone — one of only two loci reaching genome-wide significance. Men with the T allele had lower mean serum testosterone than those with the C allele. The variant explained 0.6% of the variance in serum testosterone concentrations in the MrOS Sweden replication cohort, making it a modest but reliably detected effect at the population level.

Jin et al. 2012 (Human Molecular Genetics), examining 3,225 men in an Australian cohort, independently confirmed the FAM9B locus at genome-wide significance (p=1.61×10⁻⁸)³³ Jin et al. 2012 (Human Molecular Genetics), examining 3,225 men in an Australian cohort, independently confirmed the FAM9B locus at genome-wide significance (p=1.61×10⁻⁸)
Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. The same study also found a nominally significant association with dihydrotestosterone (DHT; p=1.10×10⁻⁵), suggesting the variant may influence the full androgen cascade rather than testosterone alone. The minor allele (C, ~28% MAF in this Australian cohort) was associated with higher levels.

A 2018 meta-analysis extending the search to circulating estrogen levels in men, Eriksson et al. 2018 (J Clin Endocrinol Metab)⁴⁴ Eriksson et al. 2018 (J Clin Endocrinol Metab)
Genetic determinants of circulating estrogen levels and evidence of a causal effect of estradiol on bone density in men, also identified rs5934505 at the FAM9B locus at genome-wide significance (p=3.4×10⁻⁸) for estradiol levels, suggesting this Xp22 locus may influence both androgen and estrogen concentrations — consistent with the biological link between testosterone and its aromatization product estradiol.

Practical Actions

For men carrying the T allele (the majority), awareness of this testosterone- lowering predisposition is most relevant when interpreting lab results in the context of symptoms of low testosterone — fatigue, reduced libido, loss of muscle mass, or mood changes. While the T allele's effect size (explaining ~0.6% of variance) is modest at the population level, it compounds with other testosterone-relevant loci (SHBG at rs727428, JMJD1C at rs10822184) and lifestyle factors (adiposity, sleep quality, zinc status, vitamin D) that all influence the same hormone. Men with borderline testosterone levels near the lower reference range may benefit from targeted testing and consideration of whether their genetic predisposition is compounding the effect.

For women, the X-linked nature means heterozygous TC carriers and homozygous CC carriers are expected to have different androgenic tone than TT homozygotes, though specific GWAS data for women at this locus are limited since the primary studies focused on male cohorts. The testis-exclusive expression of FAM9B and FAM9A suggests the primary mechanism is testicular in origin, with the X-linkage creating a dose asymmetry in women that may have milder hormonal consequences.

Interactions

Rs5934505 is one of a small set of confirmed testosterone-associated loci. The SHBG locus (rs727428, chromosome 17) is the strongest autosomal testosterone determinant through its regulation of sex hormone-binding globulin — which controls the ratio of free to total testosterone. The JMJD1C locus (rs10822184, chromosome 10) affects androgen levels through a different pathway. Men carrying the T allele at rs5934505 alongside testosterone-lowering variants at SHBG or JMJD1C may have compounded reductions in circulating androgen that approach the threshold for clinical concern.

CYP17A1 rs743572, which encodes a promoter variant of the rate-limiting steroidogenic enzyme, is in a separate category as it affects androgen precursor synthesis in the adrenal and gonadal steroidogenesis cascade. The FAM9B Xp22 locus is most likely acting through a distinct, testis-local mechanism rather than a shared pathway.

Your skin color is not simply on or off — it is the result of a molecular competition between two opposing signals in every melanocyte. On one side is α-melanocyte stimulating hormone (α-MSH), which binds the melanocortin-1 receptor (MC1R) and drives eumelanin (brown-black pigment) production. On the other side is agouti signaling protein (ASIP), a secreted antagonist that blocks MC1R and pushes melanocytes toward pheomelanin (red-yellow pigment). The rs6058017 variant in ASIP — located 25 bases downstream of the gene's stop codon in the 3' untranslated region — is a key dial controlling how much ASIP protein your melanocytes produce, and therefore how dark your constitutive pigmentation tends to be.

The Mechanism

The rs6058017 A>G substitution lies in the 3' untranslated region (3'UTR) of ASIP — the tail of the messenger RNA that controls transcript stability, translation efficiency, and protein output. The G allele (ancestral, more common in African populations) causes premature mRNA degradation and message instability¹¹ premature mRNA degradation and message instability
Voisey et al., 2006, quantitative RT-PCR in human skin biopsies. Cells carrying the AA genotype produce roughly 12 times more ASIP mRNA than cells carrying the AG genotype, meaning AA individuals flood their melanocytes with ASIP protein that actively suppresses eumelanin synthesis. In contrast, G allele carriers have less ASIP, leaving MC1R signaling relatively unopposed — α-MSH can bind freely, activate cAMP cascades, upregulate MITF and tyrosinase, and drive robust eumelanin production. The result is a genetically encoded tendency toward darker skin, hair, and eye color in G allele carriers.

The A allele, which rose to high frequency in European populations through positive selection, increases ASIP expression and tips the balance toward pheomelanin synthesis. Because pheomelanin provides substantially less UV photoprotection than eumelanin — and may even generate reactive oxygen species under UV irradiation that compound DNA damage — individuals with the AA genotype carry a constitutional vulnerability to ultraviolet injury despite appearing to have "normal" European-type skin.

The Evidence

The pigmentation associations of rs6058017 were first reported by Kanetsky et al. in 2002²² Kanetsky et al. in 2002
147 healthy Caucasian controls at the University of Pennsylvania, melanoma cases excluded. Carriage of the G allele was significantly associated with dark hair (OR 1.8, 95% CI 1.2–2.8) and brown eyes (OR 1.9, 95% CI 1.3–2.8) after adjustment for age and sex. Homozygous GG carriers showed an even stronger signal, though the small GG sample (n=9) limited statistical power. The functional basis for this association was established by Voisey et al. in 2006³³ Voisey et al. in 2006
Australian European and indigenous Australian skin biopsies, who used quantitative RT-PCR to demonstrate the 12-fold difference in mRNA abundance between AA and AG genotypes. The same study found the G allele significantly more frequent in indigenous Australians than European Australians, consistent with the ancestral nature of the G variant. A complementary study by Bonilla et al. in 2005⁴⁴ Bonilla et al. in 2005
234 African Americans, skin reflectometry confirmed that the 8818G allele was associated with darker objectively measured skin color, with particularly pronounced effects in women (P<0.001).

An important distinction: rs6058017 itself has a weak and inconsistent association with melanoma risk across studies — some show modest association, others show null results. The strong skin cancer signal in the ASIP locus comes from a separate upstream haplotype defined by rs1015362 and rs4911414⁵⁵ upstream haplotype defined by rs1015362 and rs4911414
located ~110 kb upstream of ASIP coding sequence, which reached genome-wide significance for cutaneous melanoma (OR 1.45, P=1.2×10⁻⁹) and BCC (OR 1.33, P=1.2×10⁻⁶) in 2,121 melanoma cases and over 40,000 controls. This haplotype is not in strong linkage disequilibrium with rs6058017 — the two signals are partially independent. Individuals with the rs6058017 A allele carry lighter pigmentation and the biologic rationale for elevated UV risk, but direct attribution of melanoma risk to this specific variant requires additional study.

Practical Implications

Your ASIP genotype shapes your constitutive (baseline) pigmentation level, which in turn determines how much photoprotection your skin's melanin provides against UV-induced DNA damage. Individuals with the AA genotype produce more ASIP, suppress eumelanin synthesis, and tend toward lighter skin that offers less natural UV shielding. The practical implication is dose-dependent UV protection regardless of whether you tan easily: broad-spectrum SPF 30+ sunscreen daily, protective clothing when outdoors for extended periods, and annual dermatologic skin checks for those with multiple light-pigmentation variants.

The GG genotype, more common in people of West African, South Asian, and East Asian ancestry, reflects ancestrally high ASIP suppression — producing constitutively darker, more photoprotective eumelanin-rich skin. This does not eliminate melanoma risk entirely (acral and mucosal melanomas occur across pigmentation types), but the UV-driven pathway to cutaneous melanoma is substantially less active.

Interactions

The most clinically relevant interaction is between ASIP and MC1R. ASIP acts as an endogenous competitive antagonist at MC1R — so variants that weaken MC1R signaling (such as rs1805007 R151C and rs1805008 R160W, associated with red hair) interact with ASIP variants in compound fashion: both reduce eumelanin output through different mechanisms. Individuals carrying the ASIP AA genotype (high ASIP, low eumelanin) together with MC1R red-hair-color variants (impaired MC1R, reduced cAMP response to α-MSH) face a dual eumelanin deficit that may substantially amplify UV vulnerability and melanoma risk. This interaction is worth noting for those with both a pale, poorly-tanning complexion and a family history of melanoma — the compound genotype warrants more aggressive photoprotection and surveillance.

Within the ASIP locus, the relationship between rs6058017 and the upstream haplotype (rs1015362, rs4911414) is also important to understand: these signals are partially independent, and individuals carrying both the ASIP haplotype risk alleles AND the rs6058017 A allele may carry compounded risk through distinct molecular mechanisms at the same locus.

Apolipoprotein A5 (APOA5) is a liver-secreted protein that acts as a critical regulator of circulating triglyceride levels. Though present in plasma at very low concentrations, APOA5 has an outsized effect on fat clearance¹¹ APOA5 has an outsized effect on fat clearance
Plasma APOA5 concentrations are 1,000-fold lower than APOA1 yet exert comparable effects on triglyceride metabolism by facilitating the activity of lipoprotein lipase (LPL)²² lipoprotein lipase (LPL)
The enzyme anchored to capillary walls that breaks down triglycerides in VLDL and chylomicrons, the enzyme responsible for breaking down fat-carrying particles in the bloodstream. The -1131T>C promoter variant (rs662799) reduces how much APOA5 the liver produces, weakening this clearance system and allowing triglycerides to accumulate in circulation.

The Mechanism

The -1131T>C change sits in the promoter region of the APOA5 gene, approximately 1,131 base pairs upstream of where gene transcription begins. The C allele (reported as the G allele on the forward genomic strand by 23andMe) impairs ribosomal translation efficiency³³ impairs ribosomal translation efficiency
In vitro studies show reduced translational efficiency of mRNA carrying the -1131C allele, resulting in lower circulating APOA5 protein levels. With less APOA5 available, LPL activity at the capillary surface is reduced⁴⁴ LPL activity at the capillary surface is reduced
APOA5 tethers LPL to heparan sulfate proteoglycans on capillary endothelium and stabilizes the enzyme, slowing the breakdown of triglyceride-rich lipoproteins (VLDL and chylomicrons). The result is slower postprandial triglyceride clearance and higher fasting triglyceride levels.

The effect is additive — each copy of the C (A on forward strand) risk allele progressively reduces APOA5 expression and raises triglycerides. The variant is part of the APOA5*2 haplotype⁵⁵ APOA5*2 haplotype
A group of co-inherited APOA5 promoter variants including rs662799, rs651821, rs2072560, and rs2266788 associated with hypertriglyceridemia susceptibility.

The Evidence

The rs662799 -1131C allele is one of the most replicated genetic determinants of circulating triglycerides in the human genome. A meta-analysis of 51,868 participants⁶⁶ meta-analysis of 51,868 participants
Including 46 East Asian studies, 26 European studies, and 19 studies of other ethnic groups confirmed the C allele raises fasting triglycerides by a weighted mean difference of 0.30 mmol/L (about 26 mg/dL) and increases metabolic syndrome risk with an OR of 1.33 (95% CI 1.16–1.53) in the overall population. In a Hong Kong and Guangzhou Chinese cohort, plasma triglycerides were 36.1% higher in CC versus TT homozygotes⁷⁷ plasma triglycerides were 36.1% higher in CC versus TT homozygotes
OR for hypertriglyceridemia ≥1.7 mmol/L was 2.22 (1.44–3.43) for CC and 1.81 (1.37–2.39) for TC.

The cardiovascular consequences are also significant. A meta-analysis of 49,806 individuals⁸⁸ meta-analysis of 49,806 individuals
21,378 CHD cases and 28,428 controls across 10 ethnic populations showed the C allele significantly increases coronary heart disease risk (OR ~1.27 at the allele level, P < 0.00001), with consistent effects across Chinese, other Asian, and Caucasian populations.

Practical Actions

The dietary implications of this variant are particularly clear. C allele carriers appear to have a blunted metabolic response to caloric restriction and dietary fat improvement⁹⁹ C allele carriers appear to have a blunted metabolic response to caloric restriction and dietary fat improvement
Caucasian obese subjects: TG reduction −19.3 vs −4.2 mg/dL in TT vs C carriers after Mediterranean diet intervention. In a study of 363 obese Caucasian subjects, TT homozygotes achieved significant reductions in triglycerides, insulin, and insulin resistance (HOMA-IR) on a hypocaloric Mediterranean-pattern diet, while C allele carriers showed no statistically significant improvement on any of these metabolic parameters.

The fat quality appears to matter more than quantity for C allele carriers. Specifically, high n-6 polyunsaturated fat intake exacerbates the adverse effect¹⁰¹⁰ high n-6 polyunsaturated fat intake exacerbates the adverse effect
Dietary n-6 PUFA intake modulates the APOA5 effect on plasma TG and remnant lipoprotein concentrations of the risk allele on triglycerides, suggesting that correcting an omega-6:omega-3 imbalance is especially important. Increasing EPA and DHA intake through fatty fish or high-dose fish oil supplements is the most evidence-based strategy for reducing triglycerides in C allele carriers whose lifestyle interventions have had limited effect.

Monitoring fasting triglycerides regularly allows early detection of deterioration before cardiovascular risk accumulates. A fasting TG above 1.7 mmol/L (150 mg/dL) is the threshold for the metabolic syndrome criterion and a reasonable alert level for C allele carriers to intensify dietary and supplementation efforts.

Interactions

The rs662799 variant is part of the APOA5*2 haplotype, which co-segregates with other APOA5 variants — notably rs651821 (-3A>G), rs2072560 (715G>T), and rs2266788 (1891T>C). These variants are in partial linkage disequilibrium and collectively define haplotype-level triglyceride risk. Having multiple APOA5 risk alleles compounds the effect.

APOA5 interacts with the APOE genotype in determining triglyceride clearance and cardiovascular risk. APOE4 carriers (rs429358) with a concurrent APOA5 risk allele may have amplified dyslipidemia because both proteins affect VLDL metabolism through overlapping but distinct pathways — APOE governs VLDL receptor binding while APOA5 controls LPL activity. Individuals with both variants may benefit most from aggressive triglyceride management.

The rs3135506 variant (APOA5*3, Ser19Trp) is separately and independently associated with hypertriglyceridemia through a different mechanism (reduced LPL binding affinity). Carrying both rs662799 and rs3135506 risk alleles represents a compounded impairment in triglyceride clearance capacity.

Interferon Regulatory Factor 5 (IRF5) is a master transcription factor for type I interferon production and proinflammatory cytokine secretion — a molecular switch that, when overactive, drives the chronic immune activation underlying systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren syndrome. rs729302 sits approximately 9 kilobases upstream of the IRF5 coding sequence in the 5' promoter region, where it serves as the key tag SNP¹¹ tag SNP
A variant in linkage disequilibrium with the true causal variant; used to track haplotypes when the causal site is unknown or difficult to genotype for a cluster of protective haplotypes that dampen interferon output. While rs10488631 (already documented separately) marks the 3' risk haplotype block that amplifies IRF5 activity, rs729302 marks an opposing 5' protective block — the other end of a molecular rheostat controlling how loudly your immune system broadcasts the interferon alarm.

The Mechanism

The rs729302 variant is an A-to-C substitution in the 5' regulatory region of IRF5. The common A allele is the reference (risk-direction) allele; the C allele is the minor allele that tags the protective haplotypes. In luciferase reporter gene assays using lymphoblastoid cells, the C allele showed borderline increased transcriptional activity and additional transcription factor binding relative to the A allele in electrophoretic mobility shift assays²² C allele showed borderline increased transcriptional activity and additional transcription factor binding relative to the A allele in electrophoretic mobility shift assays
Fernández-Hernández et al. 2013, Arthritis Research & Therapy; the functional difference was modest, suggesting rs729302 itself may not be causal but rather tags a nearby causal regulatory element.

The protective haplotypes tagged by rs729302-C reside in the 5' side of the IRF5 locus and are functionally distinct from — and independent of — the three-block risk haplotype system anchored by rs2004640, the exon 6 INDEL, and rs10488631. Conditional analysis in the landmark 14-cohort European SLE study demonstrated that the protective signal from rs729302 persisted after conditioning on all known susceptibility variants³³ persisted after conditioning on all known susceptibility variants
Including rs10488631, rs2004640, and the CGGGG promoter indel — indicating the protective signal is not simply an absence of risk alleles, establishing it as a genuinely independent protective locus within the gene. Subsequent work in the comprehensive HMG haplotype study found that the rs729302 association signal is partially explained by linkage disequilibrium with the CGGGG insertion-deletion polymorphism⁴⁴ linkage disequilibrium with the CGGGG insertion-deletion polymorphism
A 5-bp indel in the IRF5 promoter that creates or destroys an Sp1 transcription factor binding site, altering basal IRF5 transcription, but the variant remains the best available tag SNP for this protective haplotype block on current genotyping arrays.

The Evidence

The foundational evidence for rs729302 comes from the same landmark 14-cohort European study that identified rs10488631 as the leading IRF5 susceptibility signal. Examining 1,383 SLE cases and 1,614 controls, Ferreiro-Neira et al. found that two SNPs at the IRF5 locus showed independent and opposed associations⁵⁵ two SNPs at the IRF5 locus showed independent and opposed associations
Susceptibility: rs10488631, P<10⁻¹⁷; protection: rs729302, P<10⁻⁶. The protective signal from rs729302 was statistically independent of the susceptibility signal, meaning individuals can carry both — their net interferon tone reflecting a balance between the two haplotype blocks.

The protective direction is consistent across diseases and populations. In rheumatoid arthritis, a meta-analysis of five case-control studies (6,582 RA cases and 5,375 controls)⁶⁶ meta-analysis of five case-control studies (6,582 RA cases and 5,375 controls)
Han et al. 2009, Journal of Rheumatology confirmed the C allele is protective (random-effects OR=0.889, 95% CI 0.803–0.977, P=0.015). The same study found that allele frequencies differ meaningfully between cases and controls — the C allele is enriched in the healthy population relative to disease patients, a pattern seen across cohorts.

In Korean SLE patients, rs729302 showed the same directionality: the A allele was enriched in cases (frequency 0.729) compared to controls (frequency 0.680), yielding OR=1.27 (95% CI 1.08–1.49, P=0.0037)⁷⁷ OR=1.27 (95% CI 1.08–1.49, P=0.0037)
Shin et al. 2007, Arthritis Research & Therapy; Korean study mirroring European findings for the risk A allele. In Japanese RA patients, the A allele showed OR=1.22 (P<0.001) for disease susceptibility, with a particularly strong effect in HLA shared-epitope-negative patients (OR=1.50), suggesting rs729302 captures a distinct autoimmune pathway⁸⁸ suggesting rs729302 captures a distinct autoimmune pathway
One independent of the classical HLA shared epitope mechanism that dominates seropositive RA.

The C allele frequency in controls (approximately 32% in Europeans) versus cases (approximately 27%) in the Swedish SLE cohort represents a meaningful enrichment of the protective allele in the healthy population — quantitatively modest per allele, but clinically meaningful across a locus with such broad autoimmune relevance.

Practical Implications

Carrying one or two copies of the C allele at rs729302 indicates your IRF5 locus carries partial or full protective haplotype coverage in the 5' regulatory region. This does not confer immunity to autoimmune disease — environmental triggers, other genetic variants (including the 3' risk haplotype tagged by rs10488631), and stochastic immune events all play important roles. However, the C allele is measurably associated with lower interferon output and reduced disease susceptibility across multiple autoimmune conditions.

The most clinically relevant implication is in the context of the full IRF5 haplotype: individuals who carry the rs729302-C protective allele alongside the rs10488631-T (non-risk) allele have the lowest IRF5-mediated autoimmune risk, while those who carry rs729302-A alongside rs10488631-C face the highest. The intermediate scenarios — carrying protective alleles at one locus and risk alleles at the other — result in partially offsetting effects on interferon tone.

Interactions

rs729302 operates in the same IRF5 locus as rs2004640 (exon 1B splice site, documented separately) and rs10488631 (3' haplotype tag, documented separately). The three-block haplotype structure of IRF5 means individuals carry combinations of haplotypes across all three blocks simultaneously. The rs729302 protective haplotype is functionally and statistically independent of the rs10488631 susceptibility haplotype — they can coexist in the same genome, and the individual's net interferon phenotype reflects the sum of contributions across all three blocks.

The IRF5 locus also interacts additively with STAT4 (rs7574865), which encodes the signal transducer downstream of type I interferon. IRF5 drives interferon production; STAT4 amplifies cellular responsiveness to that interferon. rs729302-C carriers who also carry the STAT4 rs7574865 non-risk (CC) genotype have a double buffer — reduced production and reduced responsiveness — giving the most protected interferon pathway configuration.

Transferrin receptor 2 (TFR2) is expressed primarily in the liver, where it acts as a sensor of circulating iron — specifically, iron bound to transferrin (the blood's iron transport protein). Unlike its well-known relative TFR1, which regulates cellular iron uptake across many tissues, TFR2 in hepatocytes functions as a surveillance protein: it detects when transferrin saturation rises and signals upstream to increase hepcidin¹¹ hepcidin
A liver-derived peptide hormone that is the master regulator of systemic iron homeostasis; it blocks iron release from the gut and from macrophages production — the body's primary brake on iron absorption. rs7385804 is an intronic variant in TFR2 that tags altered expression or splicing of this receptor, and it has emerged as one of the genome-wide-significant loci for serum iron and transferrin saturation across studies of up to 48,972 participants.

The Mechanism

TFR2 sits at the intersection of two iron-sensing pathways. In hepatocytes, it forms a complex with the HFE protein (the hereditary hemochromatosis gene product) and with hemojuvelin²² hemojuvelin
BMP co-receptor HJV/RGMC, which amplifies BMP-SMAD signaling to hepcidin to amplify BMP-SMAD pathway signaling toward hepcidin transcription. When transferrin saturation is high, diferric transferrin stabilizes TFR2 on the cell surface and sustains hepcidin production; when iron falls, TFR2 is rapidly internalized and degraded, releasing the brake. rs7385804 lies in an intron of TFR2 and appears to function as a regulatory variant or expression quantitative trait locus (eQTL): the C allele is associated with lower TFR2-mediated iron sensing, resulting in measurably lower transferrin saturation and serum iron levels compared to the A allele in multiple large population studies.

The variant does not alter the TFR2 protein sequence directly — it is classified as an intron variant — suggesting its effect is mediated through altered splicing efficiency or transcriptional regulation of TFR2 in hepatic tissue, where expression is strongly restricted. In red blood cell precursors, TFR2 also partners with the erythropoietin receptor to fine-tune erythropoiesis, explaining why rs7385804 also associates with erythrocyte indices (MCH, MCV, red cell count) in large blood cell trait GWAS.

The Evidence

The TFR2 locus surrounding rs7385804 was first identified in a major GWAS of iron homeostasis markers: Benyamin et al. 2014³³ Benyamin et al. 2014
Nature Communications — GWAS of up to 48,972 subjects; TFR2 among 11 genome-wide-significant loci for serum iron and transferrin saturation; SNPs at TFR2 also modify iron markers in HFE C282Y homozygotes. Notably, TFR2 locus variants modulated iron markers specifically in individuals already at risk for hemochromatosis, indicating that TFR2 variation is most consequential when the iron-sensing pathway is already under strain.

The association with red cell indices was demonstrated in the large-scale UK Biobank analysis: Astle et al. 2016⁴⁴ Astle et al. 2016
Cell — 173,480 European-ancestry participants; rs7385804-A associated with higher MCH (P=3×10⁻¹¹⁶) and MCV, and lower RBC count (P=4×10⁻⁹⁰), consistent with TFR2's dual role in iron sensing and erythropoiesis.

The most comprehensive quantification of the iron-status effect came from a meta-analysis of 246,139 participants across Iceland, the UK, and Denmark: Bell et al. 2021⁵⁵ Bell et al. 2021
Communications Biology — rs7385804-C associated with 0.057 SD lower serum iron (P=9×10⁻⁴³) and 0.062 SD lower transferrin saturation (P=3×10⁻³⁹). These effect sizes are modest at the individual level but reflect the consistent, population-wide influence of TFR2 on iron regulation.

In a Chinese study of 2,139 elderly women, An et al. 2012⁶⁶ An et al. 2012
Human Molecular Genetics — rs7385804 associated with reduced serum iron, transferrin, and transferrin saturation, though not with overt iron-deficiency anemia risk, underscoring that this variant modulates iron status continuously rather than acting as a dichotomous disease switch.

Practical Actions

For carriers of the CC genotype, the primary implication is a modestly lower set point for transferrin saturation. This is unlikely to cause symptomatic iron deficiency in well-nourished individuals, but it can shift baseline iron biomarkers into the lower-normal range and make recovery from iron-depleting events (heavy heavy periods, blood donation, intense athletic training) slower. Periodic monitoring of serum ferritin and transferrin saturation — rather than hemoglobin alone — is the most informative approach, since this variant acts upstream of the point where anemia develops. Dietary iron should emphasize heme iron sources (red meat, shellfish) for their superior bioavailability and the preference for consuming vitamin C alongside plant iron sources to maximise non-heme absorption.

For the AA majority, this variant is reassuring: a higher iron set point means the TFR2 iron-sensing arm is functioning at full capacity. Standard monitoring is appropriate.

Interactions

TFR2 variation interacts with HFE C282Y (rs1800562) in a clinically important way: variants at the TFR2 locus were shown to modify iron markers specifically in HFE C282Y homozygotes — the at-risk group for hereditary hemochromatosis. This suggests that TFR2 rs7385804 genotype may modulate the penetrance of HFE-driven iron overload, potentially explaining some of the clinical variability among C282Y homozygotes who range from asymptomatic to severe organ disease. The compound genetic effects of HFE, TFR2, TF (transferrin), and HJV have been documented in a case report of a Thai family with compounded iron dysregulation spanning from chronic anemia to motor neuron disorder (PMID 32895881). TMPRSS6 rs855791 (the TMPRSS6 Ala736Val variant) acts in the same hepcidin-regulation pathway and is the stronger genetic determinant of iron-deficiency anemia risk; cc genotypes of rs7385804 may compound mildly with TMPRSS6 risk alleles in iron-deficient individuals.

Glucokinase regulatory protein (GCKRP, encoded by the GCKR gene) acts as the master brake on hepatic glucokinase, the enzyme that drives the liver's uptake and processing of glucose. When blood glucose rises after a meal, GCKRP normally releases its grip on glucokinase, allowing the liver to process the incoming glucose load. The rs780094 variant — an intronic marker in very strong linkage disequilibrium with the coding variant rs1260326 (Pro446Leu)¹¹ rs1260326 (Pro446Leu)
r²=0.93; fine-mapping across 417 kb identified P446L as the likely causal variant — alters how tightly GCKRP controls this brake, producing a striking metabolic trade-off: lower fasting glucose but higher triglycerides.

The Mechanism

The P446L substitution²² P446L substitution
Proline-to-leucine change at position 446 of GCKRP, arising from the rs1260326 C>T coding transition in tight LD with rs780094 reduces GCKRP's sensitivity to fructose-6-phosphate (F6P), the signal that normally triggers GCKRP to re-inhibit glucokinase after glucose is processed. With this feedback loop weakened, glucokinase remains constitutively more active³³ glucokinase remains constitutively more active
Biochemical assays show P446L-GKRP has reduced inhibitory potency at physiological F6P concentrations, resulting in net increased GCK activity in hepatocytes, driving enhanced glycolytic flux through the liver. The downstream consequence is increased production of malonyl-CoA and citrate — substrates that fuel de novo lipogenesis⁴⁴ de novo lipogenesis
The liver's synthesis of fatty acids from carbohydrate precursors, which are then packaged into VLDL triglycerides and secreted into the bloodstream. This explains why the same T allele that lowers fasting glucose and insulin resistance simultaneously raises circulating triglycerides: more hepatic glucose processing means more fat synthesis. The mechanism also connects to elevated CRP⁵⁵ CRP
C-reactive protein, a liver-derived inflammatory marker elevated in metabolic syndrome and predictive of cardiovascular risk, likely through hepatic lipid accumulation and inflammatory signalling.

The Evidence

The association is among the most replicated metabolic GWAS findings in the human genome. A meta-analysis of over 45,000 individuals across 12 independent cohorts⁶⁶ A meta-analysis of over 45,000 individuals across 12 independent cohorts
Including Scandinavian, European, and other ancestral populations; Orho-Melander et al. 2008 established the rs1260326/rs780094 T allele (34% frequency) as associated with higher fasting triglycerides (P=3×10⁻⁵⁶) and lower fasting glucose (P=1×10⁻¹³). The same variant was associated with elevated CRP (P=5×10⁻⁵), connecting the hepatic lipid overload to systemic inflammation. The ARIC Study (n=14,889; 10,929 white, 3,960 Black)⁷⁷ ARIC Study (n=14,889; 10,929 white, 3,960 Black)
Atherosclerosis Risk in Communities Study; 45–64 years at baseline replicated all associations in white participants: T allele carriers had −1.93 mg/dl lower fasting glucose (P=2.3×10⁻⁷), +0.16 mmol/l higher triglycerides (P=2.4×10⁻³¹), −0.45 lower HOMA-IR (P=2.2×10⁻⁹), and +0.56 mg/l higher CRP (P=1.6×10⁻⁸). In Black participants, only triglyceride (P=0.004) and insulin (P=0.002) associations replicated, suggesting the full metabolic phenotype has some ancestry-specific expression. A meta-analysis of five studies (2,091 NAFLD cases / 3,003 controls)⁸⁸ A meta-analysis of five studies (2,091 NAFLD cases / 3,003 controls)
Nonalcoholic fatty liver disease meta-analysis; Zain et al. 2014 found the T allele increases NAFLD risk with OR=1.25 (95% CI 1.14–1.36, P<0.00001), consistent in both Asian and non-Asian populations. This is the mechanistic corollary of the triglyceride finding: excess hepatic lipogenesis deposits fat in the liver before it reaches the bloodstream as VLDL. The cardiovascular picture is nuanced. T allele carriers have lower insulin resistance and reduced type 2 diabetes risk — genuinely favorable effects. However, persistently elevated triglycerides and CRP, combined with NAFLD susceptibility, create cardiovascular risk through pathways distinct from the traditional insulin resistance model. The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study⁹⁹ Ludwigshafen Risk and Cardiovascular Health (LURIC) Study
Case-control study of stable coronary artery disease patients; Kozian et al. 2010 found that despite elevated TG and free fatty acids, GCKR risk allele carriers did not have significantly elevated CHD risk — suggesting the TG elevation is of the larger, buoyant particle type that may be less atherogenic than small dense LDL. Surveillance of the full lipid profile context remains warranted.

Practical Actions

The key genotype-specific action for T allele carriers is limiting dietary substrates that amplify de novo lipogenesis. Fructose and refined carbohydrates are the primary drivers of hepatic fat synthesis; because the GCKR variant already keeps glucokinase constitutively active, high carbohydrate loads — especially fructose — cause proportionally greater hepatic triglyceride production than in non-carriers. Reducing added sugar (particularly fructose from sweetened beverages and processed foods) directly reduces the substrate load feeding the overactive lipogenic pathway. Omega-3 fatty acids (EPA and DHA) specifically suppress hepatic VLDL triglyceride secretion and reduce de novo lipogenesis at a transcriptional level, addressing the downstream consequences of elevated glucokinase activity. Postprandial triglyceride responses are also elevated in T allele carriers during fat challenges, making regular monitoring of fasting triglycerides valuable for early detection of worsening lipid profiles. Annual liver function tests can catch early NAFLD progression before it becomes symptomatic.

Interactions

The rs780094 intronic variant is in near-perfect LD (r²=0.93) with the coding rs1260326 (P446L) variant; these essentially represent the same signal, with P446L identified as the likely causal substitution. Databases and consumer chip reports may list either rsid depending on which was directly genotyped. The combined effect of rs780094 (GCKR) and rs1799884 (GCK promoter variant) on type 2 diabetes has been studied in Han Chinese populations. Carrying T alleles at both loci showed additive effects on fasting glucose reduction. The interaction is relevant because GCK and GCKR act in the same regulatory complex in hepatocytes; functional variants in both could alter the glucose-sensing setpoint in an amplified way. The NAFLD risk from GCKR rs780094 T allele carriers is compounded by co-carriage of the PNPLA3 rs738409 G allele (an independent NAFLD risk variant), with carriers of both variants showing substantially higher steatosis burden than carriers of either alone. This compound effect has been documented in multiple cohorts and represents a clinically important interaction.

At chromosome 17q21 sits one of the most consequential regulatory loci in human immunology — a ~130-kb haploblock containing ORMDL3¹¹ ORMDL3
Orosomucoid-like protein 3; a transmembrane protein anchored in the endoplasmic reticulum that regulates sphingolipid biosynthesis, ICAM-1 expression, and the unfolded protein response, all of which influence airway epithelial responses to viral infection and allergen challenge, GSDMB (gasdermin B), IKZF3 (Aiolos), ZPBP2, and GSDMA. Genetic variants across this locus associate with childhood asthma, allergic rhinitis, multiple sclerosis, inflammatory bowel disease, primary biliary cholangitis, and ankylosing spondylitis — a remarkable span of inflammatory phenotypes controlled by a single regulatory neighbourhood.

rs12946510 at GRCh38 chr17:39,756,124 is an intergenic variant that sits within a chromatin-accessible enhancer element flanking the IKZF3 gene on the distal end of the 17q21 haploblock. It is one of the few 17q21 variants with direct experimental validation of its functional mechanism.

The Mechanism

The C allele at rs12946510 maintains a FOXO1 binding motif²² FOXO1 binding motif
Forkhead box protein O1 (FOXO1) is a transcription factor essential for B cell development, germinal centre reactions, and immune tolerance; it binds DNA at the sequence GTAAACA; the C allele of rs12946510 preserves this sequence while the T allele disrupts it, as well as binding sites for MEF2A and MEF2C (myocyte enhancer factor family members critical for lymphocyte differentiation). The T allele disrupts all three of these transcription factor binding sites, reducing the enhancer's activity and consequently lowering expression of ORMDL3, GSDMB, and IKZF3 in immune cells.

CRISPR/Cas9 editing³³ CRISPR/Cas9 editing
Ustiugova et al. Biochim Biophys Acta Mol Basis Dis 2023; isogenic T helper cell lines bearing CC, CT, or TT genotypes at rs12946510 were created and compared for gene expression and cellular activation profiles provided direct causal proof: cells carrying the T allele showed lower IKZF3 and ORMDL3 expression and reduced cellular activation. This makes rs12946510 one of the few 17q21 variants with experimentally validated functional consequence rather than just statistical association.

The consequence of this expression difference is tissue-context dependent. Higher ORMDL3 in airway epithelial cells increases ICAM-1 expression (the rhinovirus receptor), amplifies the unfolded protein response, and elevates sphingolipid signalling, collectively priming the airway for exaggerated inflammatory responses to viral and allergen challenge. By contrast, IKZF3/Aiolos normally suppresses germinal centre hyperactivation and IgE overproduction — the T allele's lower IKZF3 expression removes this brake on B cell responses, which may underlie its association with autoimmune conditions where excessive immune activation is the pathological driver.

The Evidence

The GABRIEL consortium GWAS⁴⁴ GABRIEL consortium GWAS
Moffatt et al. NEJM 2010; 10,365 asthma cases and 16,110 controls across 10 European populations; genome-wide significant signals at the 17q21 locus including the IKZF3/ORMDL3 region established the 17q21 haploblock as the most replicated childhood asthma susceptibility locus, with variants across this region — including the IKZF3 regulatory position at rs12946510 — consistently associated with asthma risk. CRISPR/Cas9 functional validation subsequently confirmed that T allele carriers at rs12946510 have lower ORMDL3 and IKZF3 expression, providing the mechanistic basis for reduced asthma susceptibility.

The systematic analysis of functional SNPs in 17q12-21⁵⁵ systematic analysis of functional SNPs in 17q12-21
Ustiugova et al. Genes 2019; bioinformatic prediction of transcription factor binding across all 17q21 SNPs; reporter assays in three cell types; rs12946510 had the strongest functional prediction of any variant tested identified rs12946510 as the variant with the greatest predicted impact on transcription factor binding in the entire 17q21 locus — with over 20-fold changes in MEF2A, MEF2C, FOXO1, SOX3, and SOX6 binding affinity. The primary biliary cholangitis study⁶⁶ primary biliary cholangitis study
Hitomi et al. Sci Rep 2017; eQTL analyses of rs12946510 in whole blood and spleen; T allele significantly associated with lower ORMDL3 and GSDMB expression confirmed that the T allele's functional consequences are detectable in blood at the level of gene expression.

For multiple sclerosis, RRMS patients from Serbia⁷⁷ RRMS patients from Serbia
Stefanovic et al. J Neuroimmunol 2020; TT genotype nominal MS association; decreased ORMDL3 and GSDMB mRNA levels in TT homozygotes vs non-TT patients demonstrated the inverse phenotype: when the FOXO1 binding site is disrupted (T allele), reduced IKZF3/Aiolos expression may impair normal regulatory brake on B cell activation, predisposing to autoimmune demyelination.

Practical Implications

CC homozygotes carry both copies of the FOXO1-binding, higher-expression haplotype — the configuration associated with increased ORMDL3/GSDMB-driven airway inflammation and the highest asthma susceptibility at this locus. This variant is most clinically relevant for childhood-onset asthma and virus-triggered wheeze, where ORMDL3's role in ICAM-1 expression amplifies rhinovirus susceptibility. Tracking pulmonary function objectively during respiratory viral infections and high-allergen seasons is the highest-yield monitoring action for CC carriers.

TT homozygotes, while protected at this locus from atopic airway disease, carry the FOXO1 binding-disrupted haplotype and the consequent lower IKZF3/Aiolos expression — positioning them at the autoimmune end of the 17q21 spectrum (MS, IBD, PBC associations).

Interactions

rs12946510 operates within the same 17q21 haploblock as rs12936231 (the strongest ORMDL3 eQTL in blood), rs7216389 (the canonical childhood asthma GWAS hit), and rs2872507 (IKZF3 autoimmune variant). These variants are partly correlated but represent distinct functional positions within the 130-kb regulatory region. Carriers of risk haplotypes at multiple 17q21 positions face additive ORMDL3 expression burden, amplifying airway inflammatory priming beyond any single variant alone.

rs2872507 (IKZF3, chr17:39,884,510) is the 17q21 variant most studied for autoimmune associations — its A allele is a risk factor for rheumatoid arthritis and Crohn's disease. Individuals carrying both rs12946510-CC and rs2872507-AA represent the highest-ORMDL3, highest asthma-risk haplotype configuration at 17q21, while those carrying T alleles at rs12946510 alongside autoimmune-risk alleles at rs2872507 may face the autoimmune end of the 17q21 disease spectrum.

CD58 (LFA-3) is a cell-surface adhesion glycoprotein that anchors T-cell co-stimulation and regulatory T-cell (Treg) induction by binding CD2 on T cells. The CD58 intronic locus on chromosome 1q23 has been genome-wide significantly associated with multiple sclerosis (MS) since 2009, and four intronic variants — rs2300747, rs12044852, rs1016140, and rs1335532 — form a block of strong linkage disequilibrium that collectively shape CD58 expression. Of these, rs1335532 holds a mechanistically privileged position: it sits within the stem-loop of hsa-miR-548ac¹¹ hsa-miR-548ac
A primate-specific microRNA that evolved from a Made1 mariner-class transposable element; hosted in the first intron of CD58 and co-expressed from the same primary transcript, the microRNA whose biogenesis is directly perturbed by the MS risk allele.

Unlike rs2300747 — which tags the overall CD58 eQTL — rs1335532 (in r²=0.93 LD with the causal candidate rs1414273) is the variant whose alleles physically alter the RNA secondary structure of the miRNA precursor, providing the most parsimonious molecular explanation for why risk-allele carriers have lower CD58 mRNA and higher miR-548ac simultaneously. A second independent mechanism — Wnt/ASCL2 transcription factor binding — operates specifically through the G allele of rs1335532, adding a second layer of protection beyond the miRNA pathway.

The Mechanism

miR-548ac stem-loop disruption: rs1335532 introduces either an A or G nucleotide at a position near the base of the hsa-miR-548ac stem-loop, in near-complete LD with the causal SNP rs1414273 which sits exactly at the stem base. The A allele creates a Watson-Crick A-U base pair²² Watson-Crick A-U base pair
A canonical base-pair with full hydrogen bonding; the Drosha-DGCR8 complex recognises the junction between the flanking ssRNA and the dsRNA stem; canonical pairs at this position may alter the geometry of Drosha recognition at the stem base, while the G allele creates a wobble G-U pair. The A allele configuration enhances Drosha cleavage efficiency, producing more pre-miRNA and therefore more mature miR-548ac — but at the cost of reducing the primary transcript available for CD58 mRNA production. The net result is an eQTL paradox: the same A allele that increases MS risk simultaneously raises miR-548ac levels and lowers CD58 mRNA levels in peripheral blood.

ASCL2/Wnt transcription factor axis: Independently of the miRNA mechanism, Afanasyeva et al. 2018³³ Afanasyeva et al. 2018 demonstrated that the G allele of rs1335532 creates a functional binding site for ASCL2 (Achaete-Scute Family BHLH Transcription Factor 2), a downstream effector of the Wnt signalling pathway. In B-lymphoblastoid cell lines, primary B cells, and monocytic cells, activation of Wnt signalling increased CD58 promoter activity specifically in G-allele carriers; ASCL2 knockdown abolished this effect. This mechanism operates on the transcriptional rather than the post-transcriptional level, reinforcing G-allele protection through an entirely different molecular route.

The Evidence

The miRNA mechanism was established by Hecker et al. 2019 in PLoS Genetics⁴⁴ Hecker et al. 2019 in PLoS Genetics
Blood-derived cells from ~1,000 subjects; eQTL analysis in three independent datasets (KORA, GTEx whole blood, brain); rs1335532 used as a proxy for rs1414273 at r²=0.93. Risk-allele carriers showed significantly reduced CD58 mRNA and significantly elevated hsa-miR-548ac levels across all three datasets. The concordance across independent cohorts and tissue types substantially strengthens the mechanistic inference.

The MS odds ratio associated with the risk allele at this locus ranged from 1.30 to 2.63 across cohorts in the Hecker study, with higher ORs in familial and northern European samples. The De Jager et al. 2009 PNAS study⁵⁵ De Jager et al. 2009 PNAS study
2,624 cases and 7,220 controls; genome-wide significant P = 4×10⁻⁹ for the CD58 locus; CD58 mRNA levels in MS patients positively correlated with G-allele dosage established the broader CD58 locus association, with rs1335532 one of the four variants forming the risk haplotype.

The ASCL2/Wnt mechanism reported by Afanasyeva et al. 2018 adds functional resolution to the transcriptional arm of CD58 regulation. The study used both cell line and primary cell models and confirmed the allele-specificity of ASCL2 binding by knockdown experiments, meeting standard functional validation criteria.

Population genetics mirror the MS epidemiology closely: in European populations, where MS prevalence is highest, the risk A allele is the major allele (~86%), while in East Asian populations, where MS is considerably less common, the protective G allele is the major allele (~60%). This population-frequency inversion parallels the pattern at rs2300747 and is consistent with the two variants tagging the same protective haplotype.

Practical Actions

For individuals carrying the AA genotype — the most common configuration in Europeans — the principal modifiable lever remains vitamin D optimisation. Vitamin D drives FoxP3 expression in regulatory T cells through a parallel pathway to CD58-mediated co-stimulation, and vitamin D deficiency is an established environmental modifier of MS risk. No supplement directly compensates for reduced CD58 mRNA or elevated miR-548ac, but maintaining immune regulatory capacity through vitamin D and general inflammatory-load reduction is the most evidence-supported strategy.

For AG heterozygotes, the single protective G allele provides a partial ASCL2/Wnt boost to CD58 expression and partially normalises the miRNA balance; monitoring and vitamin D sufficiency are appropriate.

Interactions

rs1335532 is in near-complete LD (r²=0.93) with rs2300747 and in strong LD with rs12044852 (r²=0.929 for the latter pair). These three variants almost certainly tag the same functional haplotype, with rs1335532/rs1414273 being the best candidate for the causally active position by virtue of its location within the miR-548ac stem-loop. The fourth CD58 intronic variant rs1016140 has a partially independent signal (associated with NMO and autoimmune thyroid disease through distinct allelic directions), suggesting it may not be fully explained by the miRNA haplotype.

The CD58 co-stimulatory axis converges with rs6897932 (IL7R)⁶⁶ rs6897932 (IL7R)
IL7R regulates T-cell homeostasis and Treg survival, a pathway that overlaps with CD58-mediated Treg co-stimulation and rs2476601 (PTPN22), which lowers the TCR activation threshold. Individuals carrying high-risk alleles at multiple T-cell regulatory loci face compounding impairments of immune self-tolerance.

Your DNA sequence is only half the story. The other half is the epigenome — the system of chemical tags that determines which genes get expressed and when. DNMT3A (DNA methyltransferase 3 alpha) is one of the principal enzymes that writes these tags, adding methyl groups¹¹ methyl groups
A methyl group (–CH₃) attached to the cytosine base creates 5-methylcytosine, which silences gene expression without altering the underlying DNA sequence to cytosines throughout the genome. rs13420827 lies in the 3' untranslated region (3' UTR) of DNMT3A — a stretch of mRNA that controls how efficiently the cell produces DNMT3A protein — and may subtly tune the global output of this critical methylation enzyme.

The Mechanism

rs13420827 is located at chromosome 2, position 25,231,098 (GRCh38), in the 3' UTR of DNMT3A. The plus-strand reference allele is C; the alternate allele is G. DNMT3A is transcribed from the minus strand, so in the mRNA context the variant appears in the 3' untranslated tail. The 3' UTR²² 3' UTR
The region after the stop codon in an mRNA; it contains binding sites for microRNAs and RNA-binding proteins that control transcript stability and translation efficiency is a hotspot for post-transcriptional regulation: binding sites for microRNAs and RNA-binding proteins that stabilize or destabilize the transcript. A C-to-G change in this region can create or destroy such binding sites, subtly altering how much DNMT3A protein each cell produces. No functional luciferase or reporter assay has been published for rs13420827 specifically — the mechanism is inferred from the variant's location and its epidemiological associations.

DNMT3A is responsible for de novo methylation: placing new methyl marks on previously unmethylated cytosines, particularly during early development, hematopoiesis, and adult tissue maintenance. It draws its methyl groups from SAM (S-adenosylmethionine), the universal methyl donor synthesized from methionine by the one-carbon cycle. Any variant that alters DNMT3A expression therefore shifts the enzymatic demand for SAM and interacts with the adequacy of the folate-B12 methylation pathway.

The Evidence

The clearest functional signal comes from a one-carbon pathway study in ovarian cancer³³ one-carbon pathway study in ovarian cancer
Kelemen LE et al. Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Research, 2008 in 829 cases and 941 controls. Among women who took multivitamin supplements, the G allele was associated with reduced ovarian cancer risk (OR 0.8, 95% CI 0.6–1.0; p interaction=0.006). The interaction specifically with multivitamin use — and not in non-users — suggests the variant's effect is conditioned on the availability of folate and B-vitamins that sustain DNMT3A's substrate pool. This is consistent with a model in which the G allele modestly reduces DNMT3A output, and adequate methyl-donor supply partially compensates.

In gastric cancer, findings have been mixed. A case-control study in Southern China⁴⁴ case-control study in Southern China
Yang XX et al. Risk-association of DNA methyltransferases polymorphisms with gastric cancer in the Southern Chinese population. Int J Mol Sci, 2012 found rs13420827 associated with reduced gastric cancer risk under the overdominant model (OR 0.66, 95% CI 0.45–0.97, p=0.034) in 242 cases and 294 controls. A separate Chinese case-control study⁵⁵ case-control study
Zhou J et al. Association of five genetic variations in DNMT1 and DNMT3A with gastric cancer in a Chinese population. Future Oncology, 2018 found the CG/GG genotypes associated with reduced cancer risk in individuals aged ≤60, and with reduced risk of poorly differentiated or advanced-stage tumors. However, a meta-analysis covering 13 studies⁶⁶ meta-analysis covering 13 studies
Li H et al. DNMT1, DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk. EBioMedicine, 2016 (3,959 cases / 5,992 controls) found rs13420827 not significantly associated with overall gastric cancer risk. The gastric cancer evidence for this specific SNP is therefore inconsistent and should be considered emerging at best.

In a Mexican seroepidemiological study⁷⁷ seroepidemiological study
Vargas-Alarcón G et al. Helicobacter pylori infection and DNMT3a polymorphism are associated with premature coronary artery disease and subclinical atherosclerosis. Microbiol Pathog, 2022 of 561 premature coronary artery disease patients and 599 controls, individuals carrying the GG genotype together with H. pylori infection showed a significant interaction on subclinical atherosclerosis risk (p interaction=1.1×10⁻⁵). This gene-environment interaction suggests the G allele may alter methylation of inflammation-related genes in the context of chronic bacterial infection.

A neurological study in Machado-Joseph disease⁸⁸ Machado-Joseph disease
Ding D et al. Polymorphisms in DNA methylation-related genes are linked to the phenotype of Machado-Joseph disease. Neurobiol Aging, 2019 found rs13420827 associated with earlier age-of-onset (p=0.019) in 613 patients with this CAG-repeat expansion disorder. DNMT3A influences CAG repeat stability through methylation of repeat-flanking sequences, so a variant affecting DNMT3A expression may shift the threshold for repeat expansion.

Practical Actions

The actionable implications of rs13420827 center on the same methyl-donor pathway that governs all DNMT3A function. Because DNMT3A uses SAM as its methyl-group donor, ensuring adequate folate and B12 intake is particularly relevant — especially given the ovarian cancer study's finding that the G allele's effect was specifically modified by multivitamin use. G allele carriers should prioritize active, pre-methylated forms of these vitamins to maximize methyl-donor availability without relying on enzymatic conversion steps that may themselves be polymorphic (e.g., MTHFR C677T).

The H. pylori interaction found in the cardiovascular study also suggests that CG and GG carriers may benefit from monitoring for and treating H. pylori infection, given the interaction with DNMT3A methylation capacity on atherosclerosis risk.

Interactions

The most relevant interaction is with MTHFR C677T (rs1801133). MTHFR supplies 5-methyltetrahydrofolate for homocysteine remethylation to methionine, the direct precursor of SAM. Individuals carrying both reduced-function MTHFR and the G allele at rs13420827 face a dual constraint: reduced SAM supply plus possibly altered DNMT3A expression. The companion DNMT3A variant rs11683424 (an intronic variant with stress-response and immune associations) sits in the same gene and may compound any functional shift in DNMT3A activity.

The Kelemen 2008 study explicitly framed rs13420827 within the one-carbon transfer pathway, alongside MTHFR, MTRR (rs1801394), and SLC19A1 (rs1051266), highlighting that this variant's risk modification is pathway-contextual: its effects depend on how well the rest of the folate-methionine cycle is functioning.